aibioArcus raises $250 million at $17.50 a share a day after kidney cancer data
Tickers RCUS
The offering priced below the $19.10 last reported sale price. Arcus says the money goes mainly to casdatifan, its HIF-2 alpha inhibitor now in two phase 3 programs.
Key facts
- Company
- Arcus Biosciences, Inc. (NYSE: RCUS)
- News type
- Financings
- Primary source
- Arcus Biosciences
Arcus Biosciences priced an underwritten public offering of 14,285,715 shares at $17.50 each on Oct. 21, for gross proceeds of $250.0 million. The company sold all of the shares itself. Underwriters have a 30-day option to buy up to 2,142,857 more, and the deal was set to close on Oct. 23.
The price came at a discount to the market. The final prospectus says the last reported sale price on Oct. 21 was $19.10. A preliminary prospectus filed the same day gave the Oct. 20 last reported sale price as $23.75. On those figures the stock fell about 20% between the two dates, and the offering priced about 8% below the Oct. 21 price. Arcus presented the new casdatifan data at an investor event in New York beginning at 8:30 AM ET on Oct. 20, so the Oct. 20 price already followed the data, and the filings do not say why the shares fell on Oct. 21.
The details
After underwriting discounts of $1.05 a share and estimated expenses, Arcus expects net proceeds of about $234.5 million, or about $269.7 million if the underwriters take the extra shares. Jefferies, Leerink Partners and TD Securities (USA) represented the underwriters, and Evercore ISI and Mizuho joined them as joint book-running managers.
The prospectus says the money will fund research and development, "including the expansion and acceleration" of the casdatifan clinical program, plus working capital and general corporate purposes. Buyers face immediate dilution of $12.56 a share against net tangible book value as of June 30. After the deal, Arcus will have about 141.3 million shares outstanding.
The sale was made under a shelf registration filed on Feb. 25, 2026 that became effective on filing.
Context
Arcus went to market with its balance sheet already disclosed. In an 8-K filed the same day, it estimated it held about $694.0 million in cash and investments at Sept. 30, 2026, a preliminary figure not yet reviewed by its auditor. That compares with $775 million at June 30, when the company said its cash would last until at least the second half of 2028 and that it expected to end 2026 with about $600 million.
The Oct. 20 data covered all lines of kidney cancer treatment. In first-line patients, casdatifan plus the PD-1 antibody zimberelimab showed 12-month landmark progression-free survival of 69% in 30 patients. In second line, casdatifan plus cabozantinib produced median progression-free survival of 14.5 months in 43 patients. Arcus said the first-line phase 3 trial, PEAK-20, is on track to start by year-end.
This is the second $250 million raise in a year. Arcus also priced a $250 million offering in October 2025. Since then, its anti-TIGIT antibody program with Gilead ended after the discontinuation of STAR-221 and STAR-121, leaving casdatifan as the main value driver.
What it means for investors
The raise adds roughly a third to the September cash pile and arrives before the expensive part of the plan: running PEAK-1 and PEAK-20 at the same time, plus a planned registrational trial of casdatifan with tivozanib. Funding the casdatifan program through more data is sensible for a company with no product revenue.
The cost is dilution. The offering priced at $17.50, below the $19.10 last reported sale price on Oct. 21. The first-line cohorts remain small, single-arm and compared only against third-party benchmarks, as Arcus itself cautions. Randomized phase 3 results are what will settle the question.
What to watch
Arcus expects to complete PEAK-1 enrollment and start PEAK-20 by the end of 2026. Results from the PRISM-1 phase 3 trial of quemliclustat in pancreatic cancer are due in the first half of 2027. The underwriters' option to buy 2,142,857 more shares runs for 30 days from Oct. 21.